证券代码：603139 证券简称：康惠股份 公告编号：2025-079 陕西康惠制药股份有限公司 关于为控股子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股子公司对外担保总额（万元） | 11,005.68 | | 对外担保总额占上市公司最近一期经审计净资产的比例（%） | 12.84 | 一、担保情况概述 （一） 担保的基本情况 2025 年 12 月 1 日，四川春盛药业集团股份有限公司（以下简称"春盛药业"） 到期归还了成都农村商业银行股份有限公司都江堰柳河支行（以下简称"成都农 商行"）贷款 1,000 万元人民币，同日，春盛药业与成都农商行签署《流动资金 借款合同》，成都农商行拟向春盛药业提供借款 980 万元人民币，借款期限为 12 个月，借款用途为：采购中药材。陕西康惠制药股份有限公司（以下简称"公 司"）作为担保方与成都农商行签署《保证合同》，为该笔借款提供连带责任保 ...

截至发稿，康惠股份市值为22亿元。 （记者 王晓波） 每经头条（nbdtoutiao）——5年期大面积下线，3年期利率低至1.5%仍一单难求：要么"售罄"要么"额度 紧张"！中长期大额存单为何在消失？ 每经AI快讯，康惠股份（SH 603139，收盘价：22元）12月1日晚间发布公告称，截至本公告披露日， 公司为控股子公司提供担保余额约为1.07亿元，控股子公司为其全资子公司提供的担保余额为280万 元，公司及控股子公司提供担保总额占公司最近一期经审计归母净资产的12.84%。 2025年1至6月份，康惠股份的营业收入构成为：医药制造占比60.68%，医药流通占比36.79%，其他业 务占比2.53%。 ...

重要内容提示： 证券代码：603139 证券简称：康惠股份 公告编号：2025-078 陕西康惠制药股份有限公司 关于业绩补偿事项申请仲裁暨累计诉讼的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ● 案件所处的仲裁阶段：咸阳仲裁委员会已受理 ● 全资子公司所处的当事人地位：仲裁申请人 ● 涉案的金额：1,414.34 万元（菩丰堂原股东张雨需支付 2023 年度和 2024 年度业绩补偿款 721.31 万元、黎勇需支付 2023 年度和 2024 年度业绩补偿款 325.30 万元、黎英需支付 2023 年度和 2024 年度业绩补偿款 162.65 万元、沈传 玖需支付 2023 年度和 2024 年度业绩补偿款 162.65 万元、沈家胜需支付 2023 年度和 2024 年度业绩补偿款 42.43 万元）及本案仲裁费用。 ● 是否会对上市公司损益产生影响：鉴于案件尚未开庭审理，仲裁结果存 在不确定性，暂无法判断对公司本期或期后利润影响。 一、业绩补偿事项的基本情况 2021 年 5 月，公司全资子公司陕西康惠 ...

Market Overview - The Chinese medicine sector experienced a decline of 0.21% on November 20, with Kanghui Co., Ltd. leading the drop [1] - The Shanghai Composite Index closed at 3931.05, down 0.4%, while the Shenzhen Component Index closed at 12980.82, down 0.76% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - *ST Changyao: Closed at 2.83, up 19.92% with a trading volume of 763,900 shares and a turnover of 197 million yuan [1] - Jinhua Co., Ltd.: Closed at 69.8, up 7.15% with a trading volume of 577,400 shares and a turnover of 505 million yuan [1] - Tailong Pharmaceutical: Closed at 7.44, up 3.33% with a trading volume of 344,200 shares and a turnover of 25.2 million yuan [1] - Conversely, Kanghui Co., Ltd. saw a decline of 3.72%, closing at 22.26 with a trading volume of 27,400 shares and a turnover of 61.69 million yuan [2] Capital Flow - The Chinese medicine sector experienced a net outflow of 143 million yuan from institutional investors, while retail investors saw a net inflow of 133 million yuan [2] - Key stocks with significant capital flow included: - Jinhua Co., Ltd.: Institutional net inflow of 99.64 million yuan, retail net outflow of 79.86 million yuan [3] - Zhongsheng Pharmaceutical: Institutional net inflow of 92.18 million yuan, retail net outflow of 51.91 million yuan [3] - Tailong Pharmaceutical: Institutional net inflow of 25.82 million yuan, retail net outflow of 31.90 million yuan [3]

重要内容提示： 一、关于新增 2025 年度日常关联交易额度的情况 （一）履行的审议程序 1、独立董事专门会议审议情况 公司于 2025 年 11 月 15 日召开 2025 年第二次独立董事专门会议，审议通过 《关于补充预计 2025 年度日常关联交易事项的议案》。全体独立董事认为：公 司及控股子公司与关联企业之间的日常关联交易，能充分利用关联方拥有的资源 和优势为公司的生产经营服务，实现资源合理配置，定价模式符合诚实、信用、 公正的原则，不存在损害公司和其他股东利益的情形，上述交易不影响公司独立 性，公司的主要业务不会因此类交易而对关联人形成依赖。全体独立董事同意《关 于补充预计 2025 年度日常关联交易事项的议案》，并同意将《关于补充预计 2025 年度日常关联交易事项的议案》提交公司第六届董事会第四次会议审议。 2、审计委员会审议情况 证券代码：603139 证券简称：康惠股份 公告编号：2025-077 陕西康惠制药股份有限公司 关于新增 2025 年度日常关联交易预计额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承 ...

Meeting Overview - The shareholder meeting was held on November 14, 2025, at the company's headquarters in Beijing [1] - The meeting was convened by the board of directors and was conducted both in-person and via online voting, presided over by Chairman Li Hongming [1] Attendance - All 9 current directors attended the meeting, along with the board secretary and senior management [2] - A witnessing lawyer from a reputable law firm was also present [2] Agenda and Resolutions - A key agenda item was the proposal for the provision of bad debt reserves for receivables, which was approved [3] - The voting process was non-cumulative, and the proposal required separate voting for minority investors [3] Legal Verification - The meeting was witnessed by lawyers from a well-known law firm, confirming that the procedures followed were in compliance with relevant laws and regulations [4][5] - The lawyers concluded that the meeting's convening, attendance, and voting processes were all legally valid [5]

Core Viewpoint - The company, Kanghui Pharmaceutical Co., Ltd., has initiated arbitration against Lai Xinsheng for a remaining performance compensation of 266 million yuan due to unmet profit commitments from a previous acquisition [2][3]. Group 1: Acquisition Background - In September 2020, Kanghui acquired 51% of Shandong Youbang Biochemical Technology Co., Ltd. for 32.64 million yuan, with Lai Xinsheng promising minimum net profits of 5 million, 10 million, and 20 million yuan for the years 2021 to 2023 respectively [3]. - If the cumulative actual net profit from 2021 to 2023 fell below the promised amount of 35 million yuan, Lai Xinsheng was obligated to compensate Kanghui with a cash payment [3][4]. - An audit revealed that Shandong Youbang incurred a cumulative loss of 72.6377 million yuan from 2021 to 2023, resulting in a compensation claim of 269 million yuan from Lai Xinsheng [3][4]. Group 2: Financial Performance and Issues - As of June 2024, Kanghui had received 2.8 million yuan in performance compensation but still awaited 266 million yuan from Lai Xinsheng [4]. - Shandong Youbang was in a state of loss and had ceased operations since 2018 due to relocation requirements from government high-speed rail projects [4][5]. - Kanghui's subsidiary, Shaanxi Youbang, has not generated the expected returns and has been continuously losing money since its consolidation in October 2020 [5][6]. Group 3: Recent Developments - In September 2023, Shaanxi Youbang announced a complete shutdown of its production due to intensified market competition and declining sales margins [6]. - On October 30, 2023, Kanghui disclosed plans to apply for bankruptcy reorganization for Shaanxi Youbang to improve its financial structure and attract strategic investors [6][7]. - As of September 30, 2025, Kanghui reported receivables of 253 million yuan from Shaanxi Youbang, with a provision for bad debts of 121 million yuan, indicating potential unrecoverable debts [7]. Group 4: Overall Company Performance - Kanghui has faced consecutive years of losses, with revenues of 492 million yuan, 673 million yuan, and 562 million yuan from 2022 to 2024, alongside corresponding losses of 63.06 million yuan, 26.16 million yuan, and 89.63 million yuan [8]. - In the first three quarters of 2025, Kanghui's revenue declined by 12% to 356 million yuan, with a net loss of 133 million yuan, exacerbated by provisions for bad debts related to Shaanxi Youbang [9].

Core Viewpoint - The company, Kanghui Pharmaceutical Co., Ltd., has initiated arbitration against Lai Xinsheng for a remaining performance compensation of 266 million yuan, stemming from a previous acquisition that has led to significant financial losses and uncertainties regarding future profits [1][2][3] Group 1: Acquisition and Performance Compensation - In September 2020, Kanghui acquired 51% of Shandong Youbang Biochemical Technology Co., Ltd. for 32.64 million yuan, with performance guarantees from Lai Xinsheng for net profits of 5 million, 10 million, and 20 million yuan for the years 2021 to 2023 [2] - Following an audit, Shandong Youbang reported a cumulative loss of 72.6377 million yuan from 2021 to 2023, leading to a compensation claim of 269 million yuan from Lai Xinsheng [2][3] - As of now, Lai Xinsheng still owes Kanghui 266 million yuan in performance compensation, despite partial payments made through a third party [3] Group 2: Financial Performance and Losses - Kanghui has reported continuous losses over the years, with revenues of 492 million yuan, 673 million yuan, and 562 million yuan from 2022 to 2024, and corresponding losses of 63.06 million yuan, 26.16 million yuan, and 89.63 million yuan [8] - In the first three quarters of 2025, Kanghui's revenue declined by 12% to 356 million yuan, with a net loss of 133 million yuan, attributed to the write-off of receivables from its subsidiary, Shaanxi Youbang [8] Group 3: Operational Challenges - Shaanxi Youbang, a subsidiary of Kanghui, has faced operational difficulties, including a complete shutdown of production due to market competition and ongoing losses, leading to plans for bankruptcy restructuring to improve its financial situation [5][6] - The company has also made significant provisions for bad debts related to Shaanxi Youbang, totaling 121 million yuan, indicating a challenging financial outlook [6] Group 4: Corporate Changes - In September 2023, Kanghui underwent a change in control, with the major shareholder shifting from Shaanxi Kanghui Holdings to Jiaxing Yuehe Zhichuang Technology Partnership, which has implications for its strategic direction [7] - Following the change in control, the company rebranded from "Kanghui Pharmaceutical" to "Kanghui Co., Ltd." to better reflect its long-term development strategy [7]

本次会议是否有否决议案：无 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603139 证券简称：康惠股份 公告编号：2025-076 陕西康惠制药股份有限公司 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 11 月 14 日 (二)股东会召开的地点：北京市昌平区超前路 17 号十纪科技大厦 10 层会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 77 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 35,278,937 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份 | 39.2459 | | 总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况等。 本次股东会由公司董事会召集，以现场和网络投票相结合的方式召开，现场 会议由公司董事长李红明先生主持。本次股东会的召集、召开和决策程 ...

北京市金杜律师事务所上海分所关于 陕西康惠制药股份有限公司 2025 年第三次临时股东会 之法律意见书 致：陕西康惠制药股份有限公司 北京市金杜律师事务所上海分所（以下简称本所）接受陕西康惠制药股份有 限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简称《证券 法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督管理委员 会《上市公司股东会规则》（以下简称《股东会规则》）等中华人民共和国境内（以 下简称中国境内，为本法律意见书之目的，不包括中国香港特别行政区、中国澳 门特别行政区和中国台湾省）现行有效的法律、行政法规、规章和规范性文件和 现行有效的《陕西康惠制药股份有限公司章程》（以下简称《公司章程》）有关规 定，指派律师出席并见证公司于 2025 年 11 月 14 日召开的 2025 年第三次临时股 东会（以下简称本次股东会），并就本次股东会相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1. 经公司 2025 年第三次临时股东大会审议批准的《公司章程》； 2. 公司 2025 年 10 月 30 日刊登于巨潮资讯网、《中国证 ...